. Author manuscript; available in PMC: 2022 Aug 4.

Published in final edited form as: Eur J Cancer. 2021 Sep 25;157:391–402. doi: 10.1016/j.ejca.2021.08.013

Table 1.

Pembrolizumab-treated patients included in the analysis.

Patients, n	Week 12 analysis			Week 24 analysis
Patients, n	KEYNOTE-001	KEYNOTE-006	Total	KEYNOTE-001	KEYNOTE-006	Total
Treatment naive or prior BRAFi	182	461	643	182	461	643
Progressed or censored before time point	82	202	284	97	240	337
Missing response at landmark	7	22	29	9	35	44
Response other than SD, PR or CR^a	7	29	36	3	18	21
Patients included in analysis, n	86	208	294	73	168	241
Treatment naive	79	177	256	68	144	212
Prior BRAFi only	7	31	38	5	24	29

BRAFi, BRAF inhibitor; CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.

Included patients with non-CR/non-PD, not available, not done or unconfirmed progression.